MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress 12 June, 2025 MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive Director and Bríd Ryan, Ph.D., MPH, as Chief Scientific Officer 20 Mar, 2025 MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting 7 December, 2024 MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases 04 April, 2024
RNAa therapeutics are a new class of medicines
Our medicines in development
Meet our passionate team

ABOUT MiNA

MiNA Therapeutics is the global leader in small activating RNA therapeutics or RNAa. Harnessing innate mechanisms of gene activation, RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.

We are advancing a proprietary pipeline of new medicines with an initial focus on genetic medicine, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of other therapeutic areas. 

PIONEERING NEW CLASS OF MEDICINES

RNAa therapeutics are an entirely new class of medicines with potential to offer transformational and curative treatment options to patients across a wide range of diseases.

CLINICALLY VALIDATED

 Our first RNAa medicine has been evaluated in clinical trials in over 130 patients and has demonstrated clinical Proof of Platform.

ROBUST PLATFORM

Our team have developed a systematic approach to take new RNAa medicines from an idea to patients in a clinical trial in just 2 years.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close